OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, has told DirectorsTalk that it has entered into a joint development agreement with Royal DSM. The agreement allows for collaboration between both parties to develop new products using OptiBiotix’s OptiBiotic® technology platform.
Royal DSM is a global science based company active in health, nutrition and materials with approximately 25,000 employees and annual net sales in the region of €10 billion. Its Nutritional Products business is one of the world’s leading suppliers of vitamins, carotenoids, nutritional lipids and other ingredients in the food, pharmaceutical and personal care industries.
If successful, the agreement allows both parties to agree commercial terms such that OptiBiotix grants an exclusive licence to DSM in the DSM field, and an option to license in other fields, in return for royalty payments on sales of future products.
Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce the signing of a joint development agreement with DSM, one of the world’s leading suppliers of nutritional ingredients. We believe that OptiBiotix’s strong science base together with DSM’s innovation focus and global reach will help both companies bring better science and better health to people around the world.”
